Skip to main content
TipRanks
Go Ultimate75% OFF

Yunkang Group Limited (2325) AI Stock Analysis

1 Followers
HK:2325

Yunkang Group Limited

(HKEX:2325)

Select Model
Rating:53Neutral
Price Target:HKD 0.52â–²(1.55% Upside)
Action:reiterated
Date:10/28/26

The score is primarily constrained by sharply declining revenue, thin profitability, and a history of losses. Improving cash flow and leverage, positive MACD, and a low P/E provide meaningful support, but overbought momentum indicators and the price remaining below its 200-day average reduce the overall strength.

Positive Factors
Cash GenerationStrong 2025 operating and free cash flow provides internal funding for operations, investment, and balance-sheet needs. The improvement across 2023–2025 suggests better cash conversion and supports resilience over the next several quarters, despite some historical volatility.
Negative Factors
Revenue ContractionThree consecutive years of revenue decline indicate a materially smaller business base and weakening top-line momentum. Continued contraction can limit operating leverage, reduce reinvestment capacity, and make the recent margin recovery harder to sustain over the medium term.

Yunkang Group Limited (2325) vs. iShares MSCI Hong Kong ETF (EWH)

-60%-40%-20%0%20%HK:2325-50.95%EWH+9.54%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 301.45M
Dividend Yield
―
Average Volume (3M)
289.38K
Price to Earnings (P/E)
5.1
Beta (1Y)
-0.17
Revenue Growth
-13.34%
EPS Growth
―
Country
Hong Kong
Employees
1,064
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Yunkang Group Limited Business Overview & Revenue Model

Company Description

Yunkang Group Limited, established in 2008 and headquartered in Guangzhou, People's Republic of China, operates as a comprehensive provider of medical operational services. The company offers a wide range of diagnostic testing solutions to medical in...

Yunkang Group Limited Financial Statement Overview

Summary

Weak revenue and profitability trends weigh heavily, despite improving leverage, positive EBIT, and stronger operating and free cash flow. Income statement score: 35; balance sheet score: 55; cash flow score: 65.

Income Statement

35Negative

Balance Sheet

55Neutral

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue540.93M601.39M711.88M891.50M3.76B1.70B
Gross Profit154.65M182.82M211.07M325.79M1.47B1.07B
EBITDA146.49M133.41M-668.52M25.07M596.45M512.57M
Net Income60.70M2.92M-791.68M-102.26M377.31M380.93M
Balance Sheet
Total Assets2.69B2.74B3.23B4.53B5.51B3.00B
Cash, Cash Equivalents and Short-Term Investments1.64B1.77B1.73B1.87B1.43B800.70M
Total Debt688.17M692.60M1.07B1.39B786.12M362.02M
Total Liabilities1.53B1.57B2.08B2.41B2.66B1.23B
Stockholders Equity1.16B1.16B1.14B2.33B2.84B1.45B
Cash Flow
Free Cash Flow0246.23M228.38M271.63M-239.05M141.06M
Operating Cash Flow0301.61M258.84M333.84M130.33M413.26M
Investing Cash Flow0313.56M354.02M-153.94M-1.25B310.72M
Financing Cash Flow0-414.36M-535.63M276.48M1.10B-215.32M

Yunkang Group Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.52

Price Trends

50DMA0.52Positive
100DMA0.58Negative
200DMA0.69Negative

Market Momentum

MACD-0.00Positive
RSI45.28Neutral
STOCH37.21Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2325, the sentiment is Negative. The current price of 0.52 is below the 20-day moving average (MA) of 0.56, below the 50-day MA of 0.52, and below the 200-day MA of 0.69, indicating a neutral trend. The MACD of -0.00 indicates Positive momentum. The RSI at 45.28 is Neutral, neither overbought nor oversold. The STOCH value of 37.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2325.

Yunkang Group Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:2325 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:3869HK:386954NeutralHKD 442.22M-136.05-0.41%―3.16%-101.02%
HK:2325HK:232553NeutralHKD 319.94M5.075.25%―-13.34%―
HK:2159HK:215953NeutralHKD 538.37M9.8328.00%―91.32%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:3886HK:388648NeutralHKD 1.22B86.190.48%1.00%-3.26%―
HK:2138HK:213847NeutralHKD 651.87M-1.62-25.36%―-8.94%-140.82%

* Healthcare Sector Average

Performance Comparison

-50%0%50%HK:2325HK:2138HK:2159HK:2279HK:3869HK:3886Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:2325 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:2325Yunkang Group Limited0.52-0.59-53.18%
HK:2138EC Healthcare0.55-0.06-9.84%
HK:2159Mediwelcome Healthcare Management & Technology Inc.1.600.3831.15%
HK:2279Yonghe Medical Group Co., Ltd.2.210.4626.65%
HK:3869Hospital Corporation of China Ltd3.20-2.68-45.58%
HK:3886Town Health International Medical Group Ltd.0.18-0.08-29.96%

Yunkang Group Limited Corporate Events

Yunkang Group to Buy 24% Stake in Chongqing Lianxin for RMB65 Million

Oct 29, 2026

Yunkang Group Limited, through a wholly owned subsidiary of Yunkang Industry, has agreed to acquire a 24.0508% equity stake in Chongqing Lianxin for RMB65 million, to be funded by internal resources and proceeds from its global offering. The consider...

Yunkang Swings to Profit Despite Revenue Drop on Cost Cuts and Efficiency Gains

Aug 28, 2026

Yunkang Group Limited, a healthcare diagnostics service provider focused on medical institution alliances, diagnostic outsourcing, and non-medical testing services in China, continues to refine its customer mix and product portfolio to strengthen its...

Yunkang Group Sets August Board Meeting to Review Interim Results and Dividend

Aug 18, 2026

Yunkang Group Limited has scheduled a board meeting for August 28, 2026 to approve its interim results for the six months ended June 30, 2026 and to authorize their publication. The directors will also consider the declaration of an interim dividend,...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026